Continuing to protect vulnerable populations during 新型冠状病毒肺炎

Continuing to protect vulnerable populations during 新型冠状病毒肺炎

As we near the third year of the 新型冠状病毒肺炎 pandemic, 在了解SARS-CoV-2病毒和寻找检测方法方面取得了实质性进展, prevent and treat 新型冠状病毒肺炎. 然而,, as the virus continues to mutate and spread, infections and hospitalisations have remained elevated in many parts of the world.1 虽然许多接种疫苗和增强免疫力的人的生活正在恢复正常, 世界上数百万没有得到新型冠状病毒肺炎疫苗充分保护的人仍然面临感染病毒的风险,如果他们被感染,严重疾病的后果也会很差.2-6

需要继续为这些人群提供保护,包括感染前和感染后, if they were to become infected.7

Who is at high risk for serious 新型冠状病毒肺炎 infection?

Vaccines remain the most important way to prevent infections as well as severe illness.8 然而, 免疫功能低下的人即使完全接种了疫苗,也可能得不到持久的保护,因为疫苗需要健康的免疫系统才能充分发挥其潜力.7,9 如果感染, these individuals may stay sicker longer, 这可能, 分别, also lead to the rise of new variants.10

免疫功能低下者(见下图)尤其有因新型冠状病毒肺炎感染而住院或死亡的风险.9 最近的研究发现:

  • 在美国,与非免疫功能低下患者相比,免疫功能低下患者占所有新型冠状病毒肺炎成人住院患者的12%,ICU住院和死亡的几率更高.11
  • 超过一半的接种过疫苗的新型冠状病毒肺炎突破性感染血癌患者住院(n=35/54).12
  • 因新型冠状病毒肺炎住院的实体器官移植受者死亡的可能性几乎是非移植患者的两倍. 也, 那些先前接受过器官移植的人在因新型冠状病毒肺炎住院期间更有可能需要通气.13

People at high-risk for serious outcomes from 新型冠状病毒肺炎


Beyond the immunocompromised, 其他人可能因年龄或其他慢性病或疾病而面临严重新型冠状病毒肺炎的高风险. The likelihood of severe illness from an infection increases with age, with adults over 65 at highest risk.9 除了, chronic conditions such as obesity, 糖尿病, heart disease and lung disease may increase the risk of serious illness from the virus.9

What are the priorities in protecting vulnerable populations?

预防新型冠状病毒肺炎并提供持久保护是免疫功能低下者等弱势群体的最终目标, especially as the virus continues to evolve.


For those who do become infected, 重点是保护那些高风险人群,避免从较轻疾病发展为严重疾病, or from needing to be hospitalised and to provide protection against future infection. As the SARS-CoV-2 virus continues to evolve, it is equally important that available therapies are able to neutralise new variants.  这群老年和脆弱患者的另一个关键考虑因素是需要不与他们已经服用的药物相互作用的治疗方法.14–16


The best way to treat 新型冠状病毒肺炎 is to prevent it in the first place. 澳门葡京赌博游戏在重症监护室看到的病人都是免疫功能低下的人,他们对疫苗没有反应, don’t clear the virus and get ill. 然后, 他们可能会服用一些药物,但这些药物也无法清除病毒,这是非常有问题的.

休•蒙哥马利 Professor of Intensive Care Medicine at University College London, UK

The road ahead for protection of vulnerable populations

As SARS-CoV-2 continues to spread around the world, 公共卫生当局建议,预防是个人降低感染covid - 19相关疾病风险的最佳策略. While it is difficult to predict what’s next for the pandemic, the current data show the newer Omicron variants, 包括英国航空公司.4和BA.5, 住院人数增加的原因是什么?预计这些趋势将继续更加强调目前的疫苗和疗法,以提供长期保护.1,17

We are dedicated to ongoing research and innovation to protect as many people as possible, 特别是医疗弱势群体,他们可能感到被忽视,需要更多保护.


主题:



有关的故事


你可能也喜欢

参考文献

1. Our World in Data Coronavirus (新型冠状病毒肺炎) Hospitalizations. Available from: http://ourworldindata.org/covid-hospitalizations#citation [Last accessed: August 2022]

2. 美国疾病控制和预防中心ACIP修改了免疫接种的免疫能力指南. Available from: http://www.疾病预防控制中心.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html [Last accessed: August 2022]

3. Deepak P等. 糖皮质激素和B细胞消耗剂严重损害MRNA疫苗对SARS-CoV-2的免疫原性. medRxiv. Published online April 9, 2021:2021.04.05.21254656.

4. Boyarsky BJ等. 单剂SARS-CoV-2信使RNA疫苗在实体器官移植受者中的免疫原性. 《澳门葡京赌博游戏》. 2021;325(17):1784-1786.

5. rabinovich等. Low Immunogenicity to SARS-CoV-2 Vaccination among Liver Transplant Recipients. J乙醇. 2021;75(2):435-438.

6. Simon D等. SARS-CoV-2 Vaccination Responses in Untreated, 常规治疗和抗细胞因子治疗的免疫介导炎性疾病患者. Ann Rheum Dis. 2021;80(10):1312-1316.

7. Infections in Immunocompromised Patients - St. Jude Children’s Research Hospital. Available from: http://www.stjude.org/treatment/patient-resources/caregiver-resources/infection-tips/infections-immunocompromised-patients.html [Last accessed: August 2022]

8. Tenforde等人. MRNA疫苗预防covid -19相关有创机械通气和死亡的有效性-美国, 2021年3月至2022年1月. MMWR Morb Mortal Wkly Rep. 2022;71(12):459-465.

9. Centers for Disease Control and Prevention People with Certain Medical Conditions. Available from: http://www.疾病预防控制中心.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html [Last accessed: August 2022]

10. 科里·L等. SARS-CoV-2 Variants in Patients with Immunosuppression. NEJM. 2021;385(6):562-566.

11. Singson JRC等. 因新型冠状病毒肺炎 - net住院的免疫功能低下成人严重结局的相关因素, 10个州, March 2020–February 2022. MMWR Morbidity and Mortality Weekly Report. 2022;71(27):878-884.

12. Schmidt等人. 新型冠状病毒肺炎 Vaccination and Breakthrough Infections in Patients with Cancer. 肿瘤学年鉴. 2022;33(3):340-346.

13. Fisher等人. 美国国家医疗保健系统住院实体器官移植受者中新型冠状病毒肺炎的结局与匹配的非移植患者队列的比较. Clinical Transplantation. 2021;35(4):e14216.

14. Conti V等. 新型冠状病毒肺炎患者药物相互作用不良事件的识别:一项系统综述. 《澳门葡京赌博游戏》网络开放. 2022;5(4):e227970-e227970.

15. Marzolini C等. 新型冠状病毒肺炎抗病毒药物Nirmatrelvir/Ritonavir (Paxlovid)与药物相互作用管理建议. 临床药理学 & 治疗. 2022年在线发布. doi: 10.1002 / CPT.2646

16. Kumar D等。. Disease-Drug and Drug-Drug Interaction in 新型冠状病毒肺炎: Risk and Assessment. Biomedicine and Pharmacotherapy. 2021;139:111642.

17. Vector Engineering Lab et al. COVID CG. Available from: http://covidcg.org/ [Last accessed: August 2022]


Veeva ID: Z4-47810
Date of preparation: October 2022